Clinical claims are the backbone of medical device marketing. When a surgeon is evaluating your device against a competitor, the claims you make about clinical performance -- procedure time reduction, complication rates, patient outcomes -- are what drive purchasing decisions. But in the medical device industry, every clinical claim you make must be substantiated, compliant, and defensible under FDA scrutiny.

I have spent 18 years helping medical device companies turn clinical data into compelling marketing messages that drive sales without crossing regulatory lines. The companies that do this well gain a massive competitive advantage. The ones that get it wrong face warning letters, product seizures, and the kind of reputational damage that takes years to repair. In this article, I am going to walk you through everything you need to know about marketing clinical claims for medical devices -- from understanding what constitutes a claim to building a sustainable claims strategy that keeps your regulatory team and your sales team equally satisfied.

What Constitutes a Clinical Claim

Before we dive into strategy, let us establish what the FDA considers a clinical claim. The definition is broader than most marketing teams realize.

A clinical claim is any statement, implication, or suggestion about the clinical performance, safety, or efficacy of a medical device. This includes:

The critical distinction is that FDA marketing compliance does not just look at what you say -- it looks at the overall impression your marketing creates. If a reasonable healthcare professional would interpret your marketing as making a clinical claim, the FDA will too, regardless of whether you used hedging language or disclaimers.

The Hierarchy of Clinical Evidence

Not all evidence is created equal in the FDA's eyes, and understanding the hierarchy of clinical evidence is essential for building a defensible claims strategy. Here is how the FDA generally views different types of evidence, from strongest to weakest:

Tier 1: Pivotal Clinical Trials (Strongest)

Randomized controlled trials (RCTs) conducted under IDE (Investigational Device Exemption) that formed the basis of your FDA clearance or approval provide the strongest foundation for clinical claims. Claims derived directly from your IDE trial data and referenced in your cleared labeling are the most defensible claims you can make.

Tier 2: Post-Market Clinical Studies

Well-designed post-market studies -- prospective, controlled, with adequate sample sizes -- can support claims beyond what your IDE trial covered, as long as those claims remain within your approved indications for use. The FDA generally expects post-market studies to be peer-reviewed and published.

Tier 3: Published Literature and Meta-Analyses

Published peer-reviewed literature about your device or substantially similar devices can support marketing claims, but with important caveats. The studies must be methodologically sound, the patient populations and use cases must align with your approved indications, and you must present the data fairly -- including any negative findings.

Tier 4: Registry Data and Real-World Evidence

Large-scale registry data and real-world evidence are increasingly recognized by the FDA as valuable, particularly for long-term outcomes data. However, the inherent limitations of observational data mean that claims based on registry data typically need more careful qualification.

Tier 5: Case Series and Case Reports (Weakest)

Individual case reports and small case series provide the weakest evidence for clinical claims. They can be used to illustrate clinical technique, but making broad performance claims based on a handful of cases is risky from a regulatory perspective.

Critical Rule: The strength of your claim should match the strength of your evidence. Making a definitive performance claim based on a case series of 12 patients is a red flag for the FDA. Making the same claim based on a 500-patient RCT is defensible. Match your language to your evidence level.

Claims Within vs. Outside Your Cleared Indications

This is where many device companies get into trouble. The FDA clearance or approval you received defines the boundaries of what you can promote. Your indications for use statement is not just a regulatory document -- it is the fence around your marketing playground.

Claims that fall within your cleared indications are permissible as long as they are substantiated and not misleading. Claims that suggest your device can be used for purposes, populations, or conditions not covered by your clearance constitute off-label promotion -- and off-label promotion is one of the FDA's top enforcement priorities.

Here is the nuance that makes this complicated: your clinical data may show excellent outcomes in patient populations or applications that are not part of your cleared indications. Your sales team will want to talk about those outcomes. Your marketing team will want to promote them. And you cannot.

What you can do:

What you cannot do:

Substantiation Requirements: What Evidence Do You Need

The FDA expects that every clinical claim you make in your marketing can be substantiated with competent and reliable evidence. But what does that mean in practice?

The standard the FDA applies is generally "competent and reliable scientific evidence," which typically means:

Importantly, the FDA does not require that you have conducted the studies yourself. You can rely on published literature, data from substantially equivalent devices, and pooled analyses. But the evidence must be relevant and reliable, and your claims must not overstate what the evidence supports.

Here is a practical framework I use with clients for evaluating whether a claim is adequately substantiated:

Practical Tip: Create a Claims Matrix -- a living document that lists every clinical claim your company makes, the specific evidence supporting each claim, the evidence tier, and the date the evidence was last reviewed. This matrix becomes your most valuable compliance tool and your first line of defense in an FDA audit. I have helped companies build these matrices, and they consistently say it is the single most impactful compliance investment they have made.

Efficacy Claims vs. Safety Claims

The distinction between efficacy claims and safety claims matters because the FDA evaluates them differently and the substantiation requirements differ.

Efficacy Claims

Efficacy claims describe what the device does -- how well it performs its intended function. Examples include procedure time reduction, visualization quality, precision of tissue removal, and clinical success rates. These claims must be substantiated with clinical data that specifically measures the claimed endpoint.

Safety Claims

Safety claims describe the absence of harm -- reduced complications, fewer adverse events, improved safety profile. Safety claims carry higher scrutiny because they directly influence risk-benefit decisions by healthcare professionals. The FDA expects robust evidence for safety claims, typically from well-controlled clinical studies with safety as a pre-specified endpoint.

The interplay between efficacy and safety claims is critical for your marketing strategy. The FDA requires "fair balance" -- meaning that your promotional materials must present both the benefits and the risks of your device. You cannot make strong efficacy claims without also disclosing relevant safety information. This is not just a legal requirement; it is a credibility requirement. Surgeons who see one-sided marketing lose trust in the company behind it.

From a regulatory marketing perspective, the most effective approach is to present both efficacy and safety data together, letting the clinical evidence speak for itself. Surgeons respect transparency, and a balanced presentation of data builds more trust than an aggressive claims strategy ever will.

How to Use Clinical Data in Marketing Materials

Translating clinical data into marketing content is both an art and a science. Here are the principles I follow:

Data Visualization

Charts, graphs, and infographics are powerful tools for presenting clinical data, but they can also be misleading. The FDA has cited companies for using truncated Y-axes that exaggerate differences, omitting error bars, and selecting timepoints that show the most favorable results. Your data visualizations must be accurate, complete, and not misleading.

Statistical Claims

When presenting statistical results, include the key metrics: sample size, p-values, confidence intervals, and the specific statistical tests used. Avoid presenting statistical significance as clinical significance -- a statistically significant difference of 0.3 minutes in procedure time may not be clinically meaningful, and presenting it as a major benefit would be misleading.

Comparative Data

If you are comparing your device to a competitor or to a control group, the comparison must be based on head-to-head data or well-matched published studies. You cannot cobble together data from different studies with different patient populations, different endpoints, and different methodologies and present it as a direct comparison.

Abstracts and Podium Presentations

Abstracts presented at medical conferences are not the same as peer-reviewed publications. While you can reference conference presentations, the FDA gives more weight to peer-reviewed published data. Be cautious about making strong claims based solely on conference abstracts, which may present preliminary data that does not hold up in the final publication.

The Role of Predicate Devices in Claims

For 510(k)-cleared devices, your clearance is based on substantial equivalence to a predicate device. This relationship has important implications for your clinical claims strategy.

You can generally reference the clinical evidence base of your predicate device, but with important limitations:

Where companies often get into trouble is claiming the clinical benefits of the predicate while also marketing design improvements that differentiate their device. If your device is different enough to market as improved, those differences may undermine your ability to rely on the predicate's clinical data. This tension requires careful navigation with your regulatory team.

Warning Signs: How to Know Your Claims Have Crossed the Line

In my experience, there are reliable warning signs that a company's clinical claims strategy has drifted into dangerous territory:

For more on how the FDA enforces these standards, read our analysis of medical device marketing requirements and what companies need to know.

Building a Sustainable Clinical Claims Strategy

The companies I work with that are most successful at clinical claims marketing share a common approach: they treat their claims strategy as a living, evidence-based program -- not a one-time exercise.

Here is the framework I recommend:

Step 1: Audit Your Current Claims

Catalog every clinical claim your company makes -- in brochures, on your website, in sales presentations, in social media, in press releases, and in training materials. For each claim, identify the supporting evidence, assess its strength, and flag any gaps.

Step 2: Build Your Claims Matrix

Create a formal claims matrix that maps each claim to its supporting evidence, the evidence tier, the marketing channels where the claim is used, and the date of last review. This becomes your single source of truth for promotional compliance.

Step 3: Align Marketing and Regulatory

The biggest obstacle to effective clinical claims marketing is the adversarial relationship that often exists between marketing and regulatory teams. Marketing wants to say more; regulatory wants to say less. The solution is to bring both teams together around the claims matrix and find the language that is both compelling and compliant. In my experience, this collaboration produces stronger marketing than either team would create alone.

Step 4: Invest in Evidence Generation

If your claims strategy reveals evidence gaps, invest in generating the data you need. Post-market studies, registries, and published case series all contribute to your evidence base. The companies with the strongest clinical claims programs are the ones that continuously invest in evidence generation -- not just to support regulatory submissions, but to fuel their marketing engine.

Step 5: Monitor the Competitive Landscape

Know what claims your competitors are making and what evidence they cite. This intelligence informs your own claims strategy and helps you identify opportunities to differentiate. It also helps you identify competitors who may be making unsupported claims -- which creates an opportunity for you to win on credibility.

Step 6: Review and Update Annually

The clinical evidence landscape evolves. New studies are published, new competitors enter the market, and your own post-market data accumulates. Review and update your claims matrix at least annually, and update your marketing materials to reflect the current state of evidence.

The Bottom Line: The most effective clinical claims strategy is not the most aggressive one -- it is the most credible one. Surgeons are sophisticated buyers who evaluate evidence critically. Claims backed by strong data, presented honestly, and consistently substantiated across all marketing channels build the kind of trust that drives long-term market share. That is the competitive advantage of doing clinical claims marketing right.

What Happens When Claims Are Not Substantiated

The consequences of making unsubstantiated clinical claims are serious and escalating:

Beyond FDA enforcement, unsubstantiated claims expose your company to competitor challenges through the National Advertising Division (NAD), the Lanham Act, and state consumer protection laws. I have seen competitor challenges that were more costly and disruptive than FDA enforcement actions.

The Competitive Advantage of Compliant Claims

I want to close with a perspective that may seem counterintuitive: compliance is a competitive advantage. In a market where many companies push the boundaries of what they can claim, the company that builds its marketing on rock-solid evidence stands out -- not as timid, but as trustworthy.

The surgeons and clinicians who buy medical devices are trained scientists. They evaluate evidence for a living. When they see a company making claims that are clearly supported by published data, presented with appropriate context and fair balance, they trust that company more than one making bold claims with thin evidence.

That trust translates into sales. It translates into surgeon loyalty. It translates into KOL relationships. And it translates into a marketing program that can sustain growth without the risk of regulatory disruption.

Build your clinical claims strategy on evidence, not aspiration. Your regulatory team, your sales team, and your bottom line will all be better for it.

Clinical Claims in Different Marketing Channels

The way you present clinical claims should vary by marketing channel, even though the underlying compliance requirements remain the same. Here is how I advise clients to approach clinical claims across their marketing mix:

Website and Digital Content

Your website is often the most content-rich channel and the best platform for detailed clinical claims. You have unlimited space to present data, context, and fair balance. Use this to your advantage. Create dedicated clinical evidence pages that present your data comprehensively, with links to published studies, data visualizations, and full risk information. These pages serve double duty as sales enablement tools -- your reps can direct surgeons to them during the evaluation process.

Print Collateral

Brochures and sell sheets have limited space, which means you need to be selective about which clinical claims you feature. Choose your strongest, most defensible claims and present them with appropriate context. Always include a reference to the full prescribing information and make it clear where healthcare professionals can access the complete clinical data.

Sales Presentations

Sales presentations are promotional materials subject to the same FDA regulations as printed brochures. Every claim in a sales deck must be approved and substantiated. The challenge is that sales reps often ad-lib during presentations, making verbal claims that go beyond the approved content. Regular training and periodic ride-along audits help keep verbal claims aligned with approved messaging.

Social Media

Social media's character and format limitations make it the most challenging channel for clinical claims. I generally advise clients to reserve clinical claims for longer-form platforms (LinkedIn articles, YouTube) and to use shorter-form platforms (X, Instagram) for brand awareness and education content that does not require extensive fair balance context.

Conference Exhibits and Podium Presentations

Conference materials -- booth graphics, handouts, and podium presentations -- must go through the same regulatory review as any other promotional material. Company-sponsored presentations by KOLs are particularly scrutinized. The data presented must be within your approved indications, and the KOL's financial relationship with the company must be disclosed.

The key principle across all channels is consistency. Your clinical claims should be the same regardless of channel -- you should never make a claim in a sales presentation that you would not put on your website, and vice versa. Channel-specific variation should be about format and depth, not about the claims themselves.

The Intersection of Clinical Claims and Sales Training

Your sales team is the front line of your clinical claims strategy, and how they communicate clinical data directly affects both your commercial success and your regulatory risk. Here is what I have learned about aligning sales training with clinical claims compliance:

First, your sales team must understand the difference between approved claims and their own clinical observations. A sales rep who has watched hundreds of procedures may have legitimate insights about device performance, but their personal observations are not approved marketing claims. They need to communicate using the language and data that have been reviewed and approved.

Second, equip your sales team with tools that make compliant selling easy. This means approved clinical data sheets, FAQs with pre-approved answers to common clinical questions, competitive comparison cards with substantiated claims, and objection-handling guides that stay within regulatory boundaries. When the compliant tools are better than the improvised alternatives, reps will use them.

Third, create a feedback loop between the field and the home office. When sales reps hear new clinical questions from surgeons, those questions should be captured, evaluated, and -- if appropriate -- addressed through new approved messaging. This feedback loop ensures your claims strategy evolves with market needs while maintaining compliance discipline.

The companies that win in competitive selling situations are not the ones making the boldest claims -- they are the ones making the most credible claims, backed by the strongest evidence, delivered by sales teams that understand both the data and the rules.